Literature DB >> 8185215

Cholecystokinin receptor family. Molecular cloning, structure, and functional expression in rat, guinea pig, and human.

S A Wank1, J R Pisegna, A de Weerth.   

Abstract

A review of the literature encompassing numerous pharmacological, physiological, and biochemical studies indicates the presence of at least four CCK receptor types, CCKA, CCKB, gastrin, and CG-4 receptors. Multiple subtypes of the CCKAR have been postulated to account for the differences in pharmacology or affinity cross-linking of CCKARs between pancreas and gallbladder and the presence of high and low affinity CCKARs on pancreatic acini. Multiple subtypes of the CCKBR have been postulated to explain the differences in pharmacology and physiology between gastric and gallbladder smooth muscle CCKBRs. We recently cloned and functionally expressed both the CCKAR and the CCKBR from rat, guinea pig, and human. The CCKAR and CCKBR are 48% homologous and constitute a family of receptors within the guanine nucleotide-binding regulatory protein-coupled superfamily of receptors. Each receptor is highly conserved between species. A single cDNA encoding a single protein is present in both pancreas and gallbladder and can account for both high and low affinity CCKARs found on pancreatic acini when transfected into COS-7 cells. A single cDNA encoding a single CCKBR protein is present in both the central nervous system and the periphery including the gastrointestinal system. Therefore, the gastrin receptor is actually a CCKBR present on parietal cells. Genomic and cDNA library hybridization as well as Northern and Southern hybridization studies among rat, guinea pig, and human species identifies only two members of the CCK receptor family, CCKAR and CCKBR. Although these studies do not identify other closely related members of the CCK receptor family, they do not rule out the existence of other less closely related members. Furthermore, differences in tissue and species-specific posttranslational processing, receptor coupling, and associated membrane protein and lipid heterogeneity may be among some of the other factors that may account for the phenotypic expression of more receptor subtypes than molecular studies would predict.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8185215     DOI: 10.1111/j.1749-6632.1994.tb44052.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  28 in total

1.  Mobilization of rat stomach ECL-cell histamine in response to short- or long-term treatment with omeprazole and/or YF 476 studied by gastric submucosal microdialysis in conscious rats.

Authors:  T Konagaya; M Bernsand; P Norlén; R Håkanson
Journal:  Br J Pharmacol       Date:  2001-05       Impact factor: 8.739

2.  Wiring and volume transmission in rat amygdala. Implications for fear and anxiety.

Authors:  Miguel Pérez de la Mora; Kirsten X Jacobsen; Minerva Crespo-Ramírez; Candy Flores-Gracia; Kjell Fuxe
Journal:  Neurochem Res       Date:  2008-05-13       Impact factor: 3.996

Review 3.  Cholecystokinin and pancreatic cancer: the chicken or the egg?

Authors:  Jill P Smith; Travis E Solomon
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-10-31       Impact factor: 4.052

4.  Electrophysiological studies of the cholecystokininA receptor antagonists SR27897B and PD140548 in the rat isolated nodose ganglion.

Authors:  P M Beart; E Krstew; R E Widdop
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-05       Impact factor: 3.000

5.  Cholecystokinin increases GABA release by inhibiting a resting K+ conductance in hippocampal interneurons.

Authors:  K K Miller; A Hoffer; K R Svoboda; C R Lupica
Journal:  J Neurosci       Date:  1997-07-01       Impact factor: 6.167

6.  Cholecystokinin A and B receptors are differentially expressed in normal pancreas and pancreatic adenocarcinoma.

Authors:  D S Weinberg; B Ruggeri; M T Barber; S Biswas; S Miknyocki; S A Waldman
Journal:  J Clin Invest       Date:  1997-08-01       Impact factor: 14.808

7.  Proliferative effects of cholecystokinin in GH3 pituitary cells mediated by CCK2 receptors and potentiated by insulin.

Authors:  A J Smith; R M McKernan
Journal:  Br J Pharmacol       Date:  1999-01       Impact factor: 8.739

8.  Pepsinogen secretion in cholecystokinin-1 receptor-deficient rats.

Authors:  Kenji Kanagawa; Hayato Nakamura; Makoto Otsuki
Journal:  Dig Dis Sci       Date:  2004-09       Impact factor: 3.199

9.  Targeted disruption of the murine cholecystokinin-1 receptor promotes intestinal cholesterol absorption and susceptibility to cholesterol cholelithiasis.

Authors:  David Q-H Wang; Frank Schmitz; Alan S Kopin; Martin C Carey
Journal:  J Clin Invest       Date:  2004-08       Impact factor: 14.808

10.  Improved kinetic stability of DTPA- dGlu as compared with conventional monofunctional DTPA in chelating indium and yttrium: preclinical and initial clinical evaluation of radiometal labelled minigastrin derivatives.

Authors:  Martin Béhé; Wolfgang Becker; Martin Gotthardt; Christa Angerstein; Thomas M Behr
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-05-24       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.